Macrogenics (MGNX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $3.37, +1.81% vs the prior close of $3.31.
- Volume 578.10K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MGNX rises 1.8% to $3.37. Closed at $3.37, +1.81% vs the prior close of $3.31. Day range $3.30–$3.43, opened at $3.34.
MGNX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — MGNX rises 1.8% to $3.37
- Closed at $3.37, +1.81% vs the prior close of $3.31. Day range $3.30–$3.43, opened at $3.34.
- Volume was 578.10K shares, 1.1x its 50-day average of 547.36K.
- Price is -14.8% vs its 50-day average ($3.96) and +0.4% vs its 200-day average ($3.36).
- 52-week range $1.29–$5.08; today's close sits at 55% of that range, 33.7% below the 52-week high.
Oct 14, 2026 — MGNX slides 3.2% to $3.31, a 3-month low, 3 down days in a row
- Closed at $3.31, -3.22% vs the prior close of $3.42. Day range $3.19–$3.42, opened at $3.42.
- Volume was 906.80K shares, 1.7x its 50-day average of 546.75K.
- Price is -16.6% vs its 50-day average ($3.97) and -1.1% vs its 200-day average ($3.35).
- 52-week range $1.29–$5.08; today's close sits at 53% of that range, 34.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — MGNX slides 8.1% to $3.42, a 3-month low
- Closed at $3.42, -8.06% vs the prior close of $3.72. Day range $3.38–$3.73, opened at $3.73.
- Volume was 559.10K shares, 1.0x its 50-day average of 545.52K.
- Price is -14.0% vs its 50-day average ($3.98) and +2.5% vs its 200-day average ($3.34).
- 52-week range $1.29–$5.08; today's close sits at 56% of that range, 32.7% below the 52-week high.
Oct 12, 2026 — MGNX dips 0.5% to $3.72
- Closed at $3.72, -0.53% vs the prior close of $3.74. Day range $3.65–$3.76, opened at $3.72.
- Volume was 284.40K shares, 0.5x its 50-day average of 548.05K — lighter than usual.
- Price is -6.7% vs its 50-day average ($3.99) and +11.8% vs its 200-day average ($3.33).
- 52-week range $1.29–$5.08; today's close sits at 64% of that range, 26.8% below the 52-week high.
Oct 9, 2026 — MGNX jumps 5.4% to $3.74
- Closed at $3.74, +5.35% vs the prior close of $3.55. Day range $3.52–$3.79, opened at $3.53.
- Volume was 418.40K shares, 0.8x its 50-day average of 545.16K.
- Price is -6.2% vs its 50-day average ($3.99) and +12.7% vs its 200-day average ($3.32).
- 52-week range $1.29–$5.08; today's close sits at 65% of that range, 26.4% below the 52-week high.
Oct 8, 2026 — MGNX ends flat (+0.0%) to $3.55, 3 down days in a row
- Closed at $3.55, +0.00% vs the prior close of $3.55. Day range $3.41–$3.62, opened at $3.53.
- Volume was 768.10K shares, 1.4x its 50-day average of 538.08K.
- Price is -11.0% vs its 50-day average ($3.99) and +7.3% vs its 200-day average ($3.31).
- 52-week range $1.29–$5.08; today's close sits at 60% of that range, 30.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — MGNX dips 2.5% to $3.55, a 3-month low
- Closed at $3.55, -2.47% vs the prior close of $3.64. Day range $3.53–$3.73, opened at $3.60.
- Volume was 510.00K shares, 0.9x its 50-day average of 545.38K.
- Price is -11.0% vs its 50-day average ($3.99) and +7.7% vs its 200-day average ($3.30).
- 52-week range $1.29–$5.08; today's close sits at 60% of that range, 30.1% below the 52-week high.
Oct 6, 2026 — MGNX slides 3.4% to $3.64
- Closed at $3.64, -3.45% vs the prior close of $3.77. Day range $3.55–$3.79, opened at $3.79.
- Volume was 633.20K shares, 1.2x its 50-day average of 546.04K.
- Price is -8.9% vs its 50-day average ($4.00) and +10.7% vs its 200-day average ($3.29).
- 52-week range $1.29–$5.08; today's close sits at 62% of that range, 28.3% below the 52-week high.
Oct 5, 2026 — MGNX jumps 5.3% to $3.77
- Closed at $3.77, +5.31% vs the prior close of $3.58. Day range $3.49–$3.86, opened at $3.65.
- Volume was 605.90K shares, 1.0x its 50-day average of 586.99K.
- Price is -5.8% vs its 50-day average ($4.00) and +15.0% vs its 200-day average ($3.28).
- 52-week range $1.29–$5.08; today's close sits at 65% of that range, 25.8% below the 52-week high.
Oct 2, 2026 — MGNX dips 0.6% to $3.58, a 3-month low
- Closed at $3.58, -0.56% vs the prior close of $3.60. Day range $3.53–$3.65, opened at $3.64.
- Volume was 980.50K shares, 1.7x its 50-day average of 578.90K.
- Price is -10.5% vs its 50-day average ($4.00) and +9.6% vs its 200-day average ($3.27).
- 52-week range $1.29–$5.08; today's close sits at 60% of that range, 29.5% below the 52-week high.
MGNX latest news & SEC filings
Every SEC filing by or about MGNX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bonvini Ezio converted options/RSUs into 8,000 shares at $2.60 (≈$20.80K) on Oct 6, 2026; now holds 193,799
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 3, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Peters Jeffrey Stuart sold 31,105 shares at $4.15 (≈$129.09K) on Aug 19, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $32.83M (prior year $6.87M) (+378.0% vs Jun 30, 2025)
- Net income: $19.52M (prior year -$36.25M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.31 (prior year -$0.57) (swung to profit vs Jun 30, 2025)
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 20, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade MGNX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 9, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.28% (largest 8.6%). That is a volatile stock.
- Liquidity: about 666.33K shares (≈$2.25M) trade per day on average.
- 52-week position: $3.37 vs a range of $1.29–$5.08 (55% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 1 sales; latest: Jeffrey Stuart Peters sold 31,105 shares on Aug 19, 2026.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 13, 2026; 8-K Jul 23, 2026.
- Share count: 63.70M shares outstanding (Aug 8, 2026), +0.8% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MGNX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 3.34 | 3.43 | 3.30 | 3.37 | 578.10K |
| Oct 14, 2026 | 3.42 | 3.42 | 3.19 | 3.31 | 906.80K |
| Oct 13, 2026 | 3.73 | 3.73 | 3.38 | 3.42 | 559.10K |
| Oct 12, 2026 | 3.72 | 3.76 | 3.65 | 3.72 | 284.40K |
| Oct 9, 2026 | 3.53 | 3.79 | 3.52 | 3.74 | 418.40K |
| Oct 8, 2026 | 3.53 | 3.62 | 3.41 | 3.55 | 768.10K |
| Oct 7, 2026 | 3.60 | 3.73 | 3.53 | 3.55 | 510.00K |
| Oct 6, 2026 | 3.79 | 3.79 | 3.55 | 3.64 | 633.20K |
| Oct 5, 2026 | 3.65 | 3.86 | 3.49 | 3.77 | 605.90K |
| Oct 2, 2026 | 3.64 | 3.65 | 3.53 | 3.58 | 980.50K |
| Oct 1, 2026 | 3.85 | 3.88 | 3.59 | 3.60 | 656.60K |
| Sep 30, 2026 | 3.76 | 3.91 | 3.73 | 3.86 | 634.10K |
| Sep 29, 2026 | 4.08 | 4.09 | 3.75 | 3.77 | 616.40K |
| Sep 28, 2026 | 3.73 | 4.11 | 3.69 | 4.06 | 1.91M |
| Sep 25, 2026 | 3.79 | 3.86 | 3.72 | 3.74 | 604.60K |
| Sep 24, 2026 | 3.80 | 3.87 | 3.62 | 3.80 | 571.30K |
| Sep 23, 2026 | 4.12 | 4.12 | 3.78 | 3.80 | 524.40K |
| Sep 22, 2026 | 4.17 | 4.20 | 4.07 | 4.12 | 377.40K |
| Sep 21, 2026 | 4.16 | 4.18 | 4.08 | 4.12 | 310.50K |
| Sep 18, 2026 | 4.12 | 4.16 | 4.09 | 4.14 | 873.90K |
About Macrogenics
Macrogenics (MGNX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in Rockville, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1125345.
MGNX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Meenu Chhabra | Director | May 20, 2026 |
| Karen Jean Ferrante | Director | May 20, 2026 |
| William K Heiden | Director | May 20, 2026 |
| Edward Hurwitz | Director | May 20, 2026 |
| Scott Thomas Jackson | Director | May 20, 2026 |
| Scott Koenig | Director | May 20, 2026 |
| Margaret Liu | Director | May 20, 2026 |
| Federica F. O'Brien | Director | May 20, 2026 |
| Eric Blasius Risser | President and CEO | Feb 17, 2026 |
| Jay Philip Siegel | Director | May 20, 2026 |
| David C Stump | Director | May 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ezio Bonvini | Sr VP, Research & CSO | Aug 18, 2026 |
| James Karrels | SVP and CFO | Feb 17, 2026 |
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary | Aug 20, 2026 |
| Eric Blasius Risser | President and CEO | Feb 17, 2026 |
| Beth Ann Smith | VP, Controller & Treasurer | Feb 17, 2026 |
| Thomas Spitznagel | Sr VP, Technical Ops | Feb 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Jeffrey Stuart Peters | Sale | 31,105 | $4.15 |
MGNX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $149.50M | $-74.62M | -1.18 | $-81.04M |
| Dec 31, 2024 | $149.96M | $-66.97M | -1.07 | $-68.37M |
| Dec 31, 2023 | $58.75M | $-9.06M | -0.15 | $-78.20M |
| Dec 31, 2022 | $151.94M | $-119.76M | -1.95 | $-86.96M |
| Dec 31, 2021 | $77.45M | $-202.12M | -3.37 | $-143.83M |
Latest balance sheet: total assets $345.41M, total liabilities $302.54M, cash $113.91M (as of Jun 30, 2026).
MGNX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $4.08 |
| May 13, 2026 | 8-K Item 2.02 (results) | $3.45 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $2.36 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.47 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $1.62 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.54 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $2.10 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $3.77 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on MGNX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.